ANAPTYSBIO, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ANAPTYSBIO, INC. (ANAB) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $42.55 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2026-09-21
- ANAPTYSBIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2025 was $228.12M, a 619.14% increase from fiscal 2024.
- ANAPTYSBIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2024 was $31.72M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|
| 2026-06-30 | $42.55M 10-KT · filed 2026-09-21 | |
| 2025-12-31 | $228.12M 10-KT · filed 2026-09-21 | |
| 2025-06-30 | $107.03M 10-KT · filed 2026-09-21 | |
| 2024-12-31 | $31.72M 10-KT · filed 2026-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |